Showing results (971-980 of 1,000) with videos related to

Sort By:
Pageof 100
Cancer Discovery|March 23, 2018
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman PrimatesAgne Taraseviciute, Victor Tkachev, Rafael Ponce, et al.
Journal of Hematology Oncology Pharmacy|September 6, 2024
Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy ActivitiesNicholas A Vitanza, Michelle Choe, Christopher Brown, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine gliomaAndrea Timpanaro, Edward Z Song, Ryma Toumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2026
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaNavin Pinto, Annette Künkele, Catherine M Albert, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2015
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL NucleasesMark J Osborn, Beau R Webber, Friederike Knipping, et al.
The New England Journal of Medicine|March 17, 2015
Long-term use of ticagrelor in patients with prior myocardial infarctionMarc P Bonaca, Deepak L Bhatt, Marc Cohen, et al.
Journal of the American Heart Association|December 21, 2018
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54Marc P Bonaca, Stephen D Wiviott, David A Morrow, et al.
Molecular Cancer Therapeutics|April 11, 2022
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma ModelShihong Zhang, R Graeme Black, Karan Kohli, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2013
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophoreDavid G Washburn, Dennis A Holt, Jason Dodson, et al.
Pageof 100